US-based biotech company X-Rx has received a major boost in its quest to develop new treatments for Idiopathic Pulmonary Fibrosis (IPF) with the US Food and Drug Administration (FDA) accepting its Investigational New Drug (IND) application for X-165, an innovative small molecule inhibitor of Autotaxin. This approval opens the door to clinical trials for X-165, […]
Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF) and cancer, has successfully raised €79 million through a Series C financing round. This funding was co-led by Ysios Capital and OrbiMed. New and Existing Investors Support Galecto Biotech’s Growth The Series C round saw participation from […]
Roivant Sciences has launched a new biopharma company, Respivant Sciences, to focus on cutting-edge treatments for severe respiratory conditions. The newly established Respivant Sciences will be led by Bill Gerhart as CEO, Ahmet Tutuncu as Executive Vice President for Clinical and Regulatory, and Pravin Soni as Executive Vice President for Development and Manufacturing. This new […]